Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

This study is testing a new injectable drug called MT1013 to see if it can lower dangerously high levels of parathyroid hormone (PTH) in people on dialysis who have a condition called secondary hyperparathyroidism — where overactive parathyroid glands weaken bones and damage other organs. **You may be eligible if...** - You are 18 or older - You have been diagnosed with secondary hyperparathyroidism related to kidney failure - You have been on regular hemodialysis (3 times per week or 5 times every 2 weeks) for at least 3 months - Your dialysate (dialysis fluid) contains an adequate calcium concentration **You may NOT be eligible if...** - You have primary hyperparathyroidism (a different type affecting the glands directly) - You are taking cinacalcet, etelcalcetide, or similar drugs and are unwilling to stop during the study - You have used bone-protecting drugs like denosumab in the past 6 months Talk to your doctor to see if this trial is right for you.